April 2021 in “Journal of Law Public Policies and Human Sciences” The described COVID-19 treatments seemed effective in influencing the disease's course, duration, and severity.
March 2021 in “Clin-Alert” The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.
January 2021 in “Online Publication Service of Würzburg University (Würzburg University)” Diphenylcyclopropenon treatment for Alopecia areata is effective and safe, improving patients' quality of life.
June 2020 in “Journal of Dermatological Treatment” Use telemedicine and strict hygiene for safe hair and scalp treatments during COVID-19.
June 2019 in “Poster presentations” Most patients with rheumatoid arthritis continued methotrexate treatment over two years, but those who stopped and restarted experienced more side effects and less improvement.
May 2019 in “Australasian Journal of Dermatology” The document discusses hair and nail conditions, updates on treatments for alopecia, and controversies around finasteride use.
March 2019 in “Applied sciences” Laser therapy might help regrow hair in alopecia totalis better than steroids alone.
May 2018 in “White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)” Alopecia areata may be treated by using EGCG to balance immune cells and reduce inflammation.
March 2014 in “Journal of The American Academy of Dermatology” The document lists various dermatology topics, treatments, and diagnostic methods.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
24 citations
,
July 2021 in “Pharmaceutics” Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
63 citations
,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
November 2025 in “Journal of Investigative Dermatology”
11 citations
,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
January 2008 in “Projeto: revista mensal de arquitetura” Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
2 citations
,
November 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
3 citations
,
June 2021 in “PLOS ONE” A topical BRAF inhibitor, vemurafenib, can speed up wound healing and promote hair growth, especially in diabetic patients.
1 citations
,
February 2025 in “International Journal of Dermatology” Abrocitinib may effectively treat Lichen Planopilaris.
September 2023 in “Acta dermato-venereologica” Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.
Ritlecitinib can reduce inflammation and help hair regrow in Alopecia Areata.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
13 citations
,
January 2020 in “Acta Dermato Venereologica” Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
January 2013 in “대한피부과학회지” Gefitinib can cause rare scarring hair loss.
July 2024 in “Journal of Investigative Dermatology” ITK inhibitors may effectively treat alopecia areata.
September 2023 in “Journal of the American Academy of Dermatology”